A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma BV
Acerta Pharma BV
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Enterome
Incyte Corporation
Incyte Corporation
Alaunos Therapeutics
BioMimetix JV, LLC
Washington University School of Medicine
BeiGene
Stemline Therapeutics, Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Karyopharm Therapeutics Inc
M.D. Anderson Cancer Center
Basilea Pharmaceutica
Lumos Pharma
Northwell Health
Novartis
Southern Illinois University
Novo Nordisk A/S
Sumitomo Pharma America, Inc.
M.D. Anderson Cancer Center
TVAX Biomedical
Rush University Medical Center
Celgene
Brown University
Weill Medical College of Cornell University
National Cancer Institute (NCI)
Boston Scientific Corporation
Radiation Therapy Oncology Group
Celgene
National Institutes of Health Clinical Center (CC)
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Gilead Sciences
Stanford University
Proximagen, LLC
National Cancer Institute (NCI)
University of California, San Francisco
AbbVie
M.D. Anderson Cancer Center
Eli Lilly and Company
Daiichi Sankyo
SCRI Development Innovations, LLC
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
Stanford University
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins